Peter Wolk, MD
Cardiovascular Disease · Chico, CANPI 1679561286
Payments from drug & device makers
Across 991 payments — averaging $56.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$23K
- Medtronic$13K
- Abbott$5K
- Amgen$2K
- Abiomed$1K
- Novartis$1K
- plus $9K from 33 others
What the payments were for
- Speaking & faculty fees$18,80034%
- Travel & lodging$10,45019%
- Food & beverage$26,08447%
- Education$2831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$21,154
- Resolute$8,884
- Confirm Rx$469
- Impella$331
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$267
- AVEIR$210
- ClosureFast$149
- HawkOne$140
- COREVALVE EVOLUT R$137
- Edwards SAPIEN 3 Transcatheter Heart Valve$136
- Mitra Clip system$132
- VYNDAQEL$125
- UNIFY ASSURA$123
- Kerendia$121
- ONYX FRONTIER$120
- LifeVest$117
- ANDEXXA$113
- Wegovy$112
- Repatha$109
- GALLANT$107
How this compares
$55,617 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 357 | $437,733 |
| XareltoRivaroxaban | 193 | $230,829 |
| EntrestoSacubitril/Valsartan | 169 | $225,532 |
| Repatha SureclickEvolocumab | 119 | $125,985 |
| JardianceEmpagliflozin | 48 | $61,435 |
| FarxigaDapagliflozin Propanediol | 35 | $40,781 |
| BrilintaTicagrelor | 47 | $40,747 |
| MultaqDronedarone Hcl | 21 | $39,869 |
| NexlizetBempedoic Acid/Ezetimibe | 33 | $19,943 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 37 | $19,686 |
| Ezetimibe | 366 | $12,577 |
| VascepaIcosapent Ethyl | 16 | $11,924 |
| Atorvastatin Calcium | 989 | $9,953 |
| Metoprolol Succinate | 536 | $8,077 |
| Midodrine Hcl | 43 | $7,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $947 | $437,733357 claims |
| Johnson & JohnsonXarelto | $23,357 | $230,829193 claims |
| NovartisEntresto | $1,465 | $225,532169 claims |
| AstraZenecaFarxiga, Brilinta | $1,093 | $81,52882 claims |
| Boehringer IngelheimJardiance | $348 | $61,43548 claims |
| Sanofi-aventis U.S. LLCMultaq | $309 | $39,86921 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $35 | $26,87459 claims |
| Esperion Therapeutics, Inc.Nexlizet | $547 | $19,94333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Chico
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.